The multi-targeting paradigm in drug discovery
Il 18/05/2018 ore 14.30 - 15.30
Sala Conferenze Cnr, Via P. Castellino, 111 80131 Napoli
Prof. Stefano Alcaro from Università 'Magna Græcia' di Catanzaro, will give a seminar on an important and emerging issue in modern drug discovery, that is designing of novel or identifying existing bioactive compounds, endowed with the capability to interact selectively with two or more macromolecular targets, exerting their effects against certain therapeutic goals in a synergic fashion (1).
This innovative concept stimulated the creation of a COST Action focusing on novel ligands able to recognize selected multiple targets, to promote closer scientific links among European research groups involved in medicinal chemistry field at both academic and industrial level. The repurposing issue is extremely interesting especially at this level, since many compounds, obtained by means of consistent scientific investigations, could be revaluated and eventually have a new future (2).
The aim of the COST Action MuTaLig (Multi-target paradigm for innovative ligand identification in the drug discovery process) is to join highly-qualified research teams working in disciplines around the field of medicinal chemistry, into a novel network devoted to the multi-target issue in drug discovery. The choice of this theme is related to its marked multidisciplinary character (3), which can ensure a strong interaction among all COST Action participants, started as 5 co-proposing European research teams and recently expanded up to more than 30 countries. The research competencies of the network will span around medicinal chemistry, from synthetic chemistry, natural products and biophysics to theoretical chemistry, molecular modelling and biological screening.
Additional details about the recently launched MuTaLig COST CA15135 Action with the support of the EU Framework program Horizon 2020 are available on line.4
References
1 Medina-Franco J. L., Giulianotti M. A., Welmaker G. S., Houghten R. A. Drug Discovery Today, 2013, 18, 495-501.
2 Peters, J.P.; Polypharmacology−Foe or Friend? J. Med. Chem., 2013, 56, 8955–8971.
3 Bolognesi, M. L.; Cavalli, A. ChemMedChem., 2016, 11, 1190-1192.
4 www.cost.eu/COST_Actions/ca/CA15135 and www.mutalig.eu
Organizzato da:
Ibp-Cnr
Referente organizzativo:
Andrea Beccari
CNR - Istituto di biochimica delle proteine
Via P. Castellino, 111 80131 Napoli
a.beccari@ibp.cnr.it
081/6132283
Modalità di accesso: ingresso libero